Targeting BCL2 pathways in CLL: a story of resistance and ingenuity

Abstract

Chronic lymphocytic leukemia (CLL) is common amongst leukemic malignancies, prompting dedicated investigation throughout the years. Over the last decade, the treatment for CLL has significantly advanced with agents targeting B-cell lymphoma 2 (BCL2), Bruton’s tyrosine kinase, and CD20. Single agents or combinations of these targets have proven efficacy. Unfortunately, resistance to one or multiple of the new treatment targets develops. Our review investigates various mechanisms of resistance to BCL2 inhibitors, including mutations in BCL2, alterations in the Bcl protein pathway, epigenetic modifications, genetic heterogeneity, Richter transformation, and alterations in oxidative phosphorylation. Additionally, the review will discuss potential avenues to overcome this resistance with novel agents such as bispecific antibodies, Bruton’s tyrosine kinase (BTK) degraders, non-covalent BTK inhibitors, and chimeric antigen receptor T (CART).

Keywords

BCl-2 inhibitors / apoptosis / CLL / resistance / tumor microenvironments / cell cycle regulation / genetic mutations / epigenetics / richter transformation

References

[1] Chronic lymphocytic leukemia - Chronic lymphocytic leukemia (CLL). Available from: https://seer.cancer.gov/statfacts/html/clyl.html. [Last accessed on 21 Nov 2023]

[2] Hallek M,Eichhorst B.Chronic lymphocytic leukaemia.Lancet2018;391:1524-37

[3] Burger JA,Barr PM.Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia.N Engl J Med2015;373:2425-37

[4] Roberts AW,Pagel JM.Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia.N Engl J Med2016;374:311-22

[5] Seymour JF,Eichhorst B.Venetoclax-rituximab in relapsed or refractory chronic lymphocytic leukemia.N Engl J Med2018;378:1107-20

[6] Jain N,Thompson P.Ibrutinib and venetoclax for first-line treatment of CLL.N Engl J Med2019;380:2095-103

[7] Tam CS,Siddiqi T.Fixed-duration ibrutinib plus venetoclax for first-line treatment of CLL: primary analysis of the CAPTIVATE FD cohort.Blood2022;139:3278-89

[8] Hillmen P,Brock K.Ibrutinib plus venetoclax in relapsed/refractory chronic lymphocytic leukemia: the CLARITY study.J Clin Oncol2019;37:2722-9

[9] Stilgenbauer S,Schetelig J.Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial.J Clin Oncol2018;36:1973-80

[10] Al-Sawaf O,Tandon M.Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial.Lancet Oncol2020;21:1188-200

[11] Roy MJ,Czabotar PE.Cell death and the mitochondria: therapeutic targeting of the BCL-2 family-driven pathway.Br J Pharmacol2014;171:1973-87

[12] Youle RJ.The BCL-2 protein family: opposing activities that mediate cell death.Nat Rev Mol Cell Biol2008;9:47-59

[13] Bose P,Konopleva M.Pathways and mechanisms of venetoclax resistance.Leuk Lymphoma2017;58:2026-39

[14] Blombery P,Gong JN.Acquisition of the recurrent Gly101Val mutation in BCL2 confers resistance to venetoclax in patients with progressive chronic lymphocytic leukemia.Cancer Discov2019;9:342-53

[15] Tausch E,Dolnik A.Venetoclax resistance and acquired BCL2 mutations in chronic lymphocytic leukemia.Haematologica2019;104:e434-7

[16] Blombery P,Nguyen T.Characterization of a novel venetoclax resistance mutation (BCL2 Phe104Ile) observed in follicular lymphoma.Br J Haematol2019;186:e188-91

[17] Fresquet V,Carolis C,Martinez-Climent JA.Acquired mutations in BCL2 family proteins conferring resistance to the BH3 mimetic ABT-199 in lymphoma.Blood2014;123:4111-9

[18] Lucas F,Gregory CT.Novel BCL2 mutations in venetoclax-resistant, ibrutinib-resistant CLL patients with BTK/PLCG2 mutations.Blood2020;135:2192-5

[19] Thomalla D,Grimm C.Deregulation and epigenetic modification of BCL2-family genes cause resistance to venetoclax in hematologic malignancies.Blood2022;140:2113-26

[20] Landau DA,Taylor-Weiner AN.Mutations driving cll and their evolution in progression and relapse.Nature2015;526:525-30

[21] Calin GA,Cimmino A.A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia.N Engl J Med2005;353:1793-801

[22] Fabris L,Calin G.Non-coding RNAs as cancer hallmarks in chronic lymphocytic leukemia.Int J Mol Sci2020;21:6720

[23] Wood S,Cheng JX.RNA cytosine methyltransferases NSUN1 and NSUN2 mediate the lineage-associated resistance to venetoclax in leukemia.Blood2020;136:13-4

[24] Blombery P,Dengler MA.Clonal hematopoiesis, myeloid disorders and BAX-mutated myelopoiesis in patients receiving venetoclax for CLL.Blood2022;139:1198-207

[25] Birkinshaw RW,Luo CS.Structures of BCL-2 in complex with venetoclax reveal the molecular basis of resistance mutations.Nat Commun2019;10:2385

[26] Al-harbi S,Mazumder S.An antiapoptotic BCL-2 family expression index predicts the response of chronic lymphocytic leukemia to ABT-737.Blood2011;118:3579-90

[27] Bennett R,Tam C.SOHO state of the art updates and next questions | mechanisms of resistance to BCL2 inhibitor therapy in chronic lymphocytic leukemia and potential future therapeutic directions.Clin Lymphoma Myeloma Leuk2022;22:795-804

[28] Niu X,Ma J.Binding of released bim to Mcl-1 is a mechanism of intrinsic resistance to ABT-199 which can be overcome by combination with daunorubicin or cytarabine in AML cells.Clin Cancer Res2016;22:4440-51

[29] Negi A.Development of Mcl-1 inhibitors for cancer therapy.Eur J Med Chem2021;210:113038

[30] Haselager MV,Ter Burg J.Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.Blood2020;136:2918-26

[31] Jayappa KD,Gordon VL.Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL.Blood Adv2017;1:933-46

[32] Döhner H,Benner A.Genomic aberrations and survival in chronic lymphocytic leukemia.N Engl J Med2000;343:1910-6

[33] Fiorcari S,Atene CG.Notch2 increases the resistance to venetoclax-induced apoptosis in chronic lymphocytic leukemia B cells by inducing Mcl-1.Front Oncol2022;11:777587

[34] Herling CD,Weiss J.Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.Nat Commun2018;9:727

[35] Guièze R.Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.Blood2015;126:445-53

[36] Lee KM,Balko JM.MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation.Cell Metab2017;26:633-47.e7

[37] Guièze R,Rosebrock D.Mitochondrial reprogramming underlies resistance to BCL-2 inhibition in lymphoid malignancies.Cancer Cell2019;36:369-84.e13

[38] Ma S,Brander DM.Efficacy of venetoclax plus rituximab for relapsed CLL: 5-year follow-up of continuous or limited- duration therapy.Blood2021;138:836-46

[39] Thijssen R,Anderson MA.Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy.Blood2022;140:2127-41

[40] Seymour JF,Popovic R.Assessment of the clonal dynamics of acquired mutations in patients (Pts) with relapsed/refractory chronic lymphocytic leukemia (R/R CLL) treated in the randomized phase 3 murano trial supports venetoclax-rituximab (VenR) fixed-duration combination treatment (Tx).Blood2021;138:1548

[41] Goy A,Kahl B,Protomastro E.A phase I/II study of the pan Bcl-2 inhibitor obatoclax mesylate plus bortezomib for relapsed or refractory mantle cell lymphoma.Leuk lymphoma2014;55:2761-8

[42] Kipps TJ,Grosicki S.A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia.Leuk Lymphoma2015;56:2826-33

[43] Roberts AW ,Brown JR .Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease.J Clin Oncol2012;30:488-96

[44] Wilson WH ,Czuczman MS .Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity.Lancet Oncol2010;11:1149-59

[45] Deng J,Fang DD.Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy.Clin Cancer Res2022;28:5455-68

[46] Davids MS,Mudenda B.Lisaftoclax (APG-2575) safety and activity as monotherapy or combined with acalabrutinib or rituximab in patients (pts) with treatment-naïve, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL): initial data from a phase 2 global study.Blood2022;140:2326-8

[47] Budde LE,Matasar M.Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study.Lancet Oncol2022;23:1055-65

[48] Bannerji R,Advani RH.Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial.Lancet Haematol2022;9:e327-39

[49] Hutchings M,Iacoboni G.Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: A Phase I trial.J Clin Oncol2021;39:1959-70

[50] Thieblemont C,Ghesquieres H.Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I/II trial.J Clin Oncol2023;41:2238-47

[51] Patel K,Tilly H.A phase 1 study of plamotamab, an anti-CD20×Anti-CD3 bispecific antibody, in patients with relapsed/refractory non-hodgkin’s lymphoma: recommended dose safety/efficacy update and escalation exposure-response analysis.Blood2022;140:9470-2

[52] Porter DL,Kalos M,June CH.Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.N Engl J Med2011;365:725-33

[53] Melenhorst JJ,Wang M.Decade-long leukaemia remissions with persistence of CD4⁺ CAR T cells.Nature2022;602:503-9

[54] Todorovic Z,Markovic V.CAR T cell therapy for chronic lymphocytic leukemia: successes and shortcomings.Curr Oncol2022;29:3647-57

[55] Siddiqi T,Kenderian SS.Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.Lancet2023;402:641-54

[56] Mato AR,Ai WZ.NX-2127-001, a first-in-human trial of NX-2127, a Bruton’s tyrosine kinase-targeted protein degrader, in patients with relapsed or refractory chronic lymphocytic leukemia and B-cell malignancies.Blood2022;140:2329-32

[57] Mato AR,Brown JR.Pirtobrutinib after a covalent BTK inhibitor in chronic lymphocytic leukemia.N Engl J Med2023;389:33-44

[58] Woyach JA,Coombs CC.BRUIN CLL-314: a phase III open-label, randomized study of pirtobrutinib (LOXO-305) versus ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.Blood2022;140:12427-8

[59] Jurczak W,Coscia M.BRUIN CLL-313: a phase 3 open-label, randomized study of pirtobrutinib versus bendamustine plus rituximab in untreated patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (trial in progress).Blood2021;138:3732

[60] Woyach JA,Awan FT.Efficacy and safety of nemtabrutinib, a wild-type and C481S-mutated bruton tyrosine kinase inhibitor for B-cell malignancies: updated analysis of the open-label phase 1/2 dose-expansion bellwave-001 study.Blood2022;140:7004-6

[61] Byrd JC,Wagner-Johnston N.First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.Oncotarget2018;9:13023-35

[62] Lannutti BJ,Herman SE.CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability.Blood2011;117:591-4

[63] Caforio M,De Angelis B.PI3K/Akt pathway: the indestructible role of a vintage target as a support to the most recent immunotherapeutic approaches.Cancers2021;13:4040

[64] Hus I,Robak T.PI3K inhibitors for the treatment of chronic lymphocytic leukemia: current status and future perspectives.Cancers2022;14:1571

[65] Mato AR,Biondo JML.The impact of early discontinuation/dose modification of venetoclax on outcomes in patients with relapsed/refractory chronic lymphocytic leukemia: post-hoc analyses from the phase III MURANO study.Haematologica2022;107:134-42